Akero Therapeutics Inc (AKRO)
38.58
+1.13 (+3.02%)
USD |
NASDAQ |
Mar 27, 10:40
Akero Therapeutics Cash from Operations (TTM): -92.52M for Dec. 31, 2022
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2022 | -92.52M |
September 30, 2022 | -93.70M |
June 30, 2022 | -83.69M |
March 31, 2022 | -84.21M |
December 31, 2021 | -79.68M |
September 30, 2021 | -76.38M |
June 30, 2021 | -75.28M |
March 31, 2021 | -77.83M |
December 31, 2020 | -70.80M |
Date | Value |
---|---|
September 30, 2020 | -59.06M |
June 30, 2020 | -58.76M |
March 31, 2020 | -41.50M |
December 31, 2019 | -35.63M |
September 30, 2019 | -26.05M |
June 30, 2019 | -14.80M |
March 31, 2019 | -9.731M |
December 31, 2018 | -4.625M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-93.70M
Minimum
Sep 2022
-4.625M
Maximum
Dec 2018
-57.90M
Average
-70.80M
Median
Dec 2020
Cash from Operations (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | -224.86M |
89bio Inc | -81.09M |
Bone Biologics Corp | -1.803M |
NovaBay Pharmaceuticals Inc | -9.763M |
Palatin Technologies Inc | -34.62M |